Therapeutic areas - Valbiotis

Prediabetes

More than 8.5% of the global adult population suffers from diabetes.

Type 2 diabetes is a chronic hyperglycemia primarily associated with excess weight and a sedentary lifestyle. This disease is spreading steadily throughout the world’s population and causes serious complications for the heart, blood vessels, eyes, kidneys and nerves. Prevention is possible at the prediabetic stage (prediabetes is reversible), and is based today on lifestyle and dietary measures. Its treatment requires a lifestyle change in combination with medication, which may increase as the disease evolves.

TOTUM•63

Dyslipidemia

39% of global population has hypercholesterolemia.

Dyslipidemia, or abnormal levels of fat in the blood, and more specifically hypercholesterolemia, are omnipresent throughout the world’s population.
Gradually blocking the arteries, these conditions contribute to the development of a number of cardiovascular diseases.
To prevent or cure these conditions, lifestyle changes are key. Medicinal treatments are recommended for patients most at risk.

TOTUM•070

Arterial hypertension

Globally, 1.1 billion people suffer from arterial hypertension, i.e. 24.1% of the population. Raised blood pressure is the leading cardiovascular risk factor in the world.

This silent disease with multiple causes (smoking, diet, sedentary lifestyle, etc.) is a precursor to various cardiovascular, kidney, brain and eye diseases. A healthy lifestyle and regular medical check-ups can effectively prevent this condition. Successful management of the disease relies on lifestyle improvements and antihypertensive treatments.

TOTUM•854

MAFLD/NAFL/NASH

The prevalence of metabolic liver diseases, including all stages, is estimated at 25% worldwide. These diseases are on the rise, with a 63% increase in NASH cases expected in 2030, compared to 2015.

NASH refers to the most advanced stage of non-alcoholic fatty liver disease, and involves a combination of fat accumulation, inflammation and lesions in the hepatocyte cells. In particular, these alterations can lead to cirrhosis or liver cancer. Associated with sedentary lifestyles and poor eating habits, this epidemic has been silently spreading across developed countries. Prevention and treatment of risk factors are the only “therapeutic” solutions currently available.

TOTUM•448

Overweight/Obesity

1.9 billion adults are overweight, worldwide (39% of the population). The number of cases has almost tripled since 1975.

Among them, 650 million people are obese.

Overweight and obesity are a major health concern affecting all industrialized countries. Overweight has been associated with a number of diseases, in particular certain cardiovascular conditions and cancers.

Management of this condition, whether therapeutic or preventive, requires extensive awareness-raising and a long-term commitment from patients to make lasting lifestyle changes.

Intestinal microbiota

Composition: 100,000 billion microorganisms (more than the number of cells in the human body).

Weight: One to three kilos. It is mainly composed of bacteria, divided into tens of species with diverse action mechanisms.

Made up of billions of microorganisms, the intestinal microbiota is essential for the human body to function properly. Alterations (dysbiosis) of the healthy microbiota are involved in the development of various diseases, including metabolic disorders such as obesity or type 2 diabetes. Correcting dysbiosis primarily involves a suitable diet, probiotic supplements and/or intestinal microbiota modulation.

Sources:
– World Health Organization, Fact sheet Diabetes, www.who.int (updated 8 June 2020);
– World Health Organization, The Global Health Observatory, www.who.int, data 2008 (% of people aged > 25, with total cholesterol ≥ 190 mg/dL);
– NCD Risk Factor collaboration, The Lancet, 2017, www.thelancet.com;
– Younossi Z. et al., Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 2016;
– Estes C et al., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;
– Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, World Gastroenterology Organisation, 2012;
– World Health Organization, Fact sheet Overweight / obesity, data 20216, www.who.int (updated 20 August 2020);
– Inserm, www.inserm.fr (updated 1st February 2016);
– Rémy Burcelin, Simon Nicolas and Vincent Blasco-Baque. Le microbiote : cet inconnu qui réside en nous, Med Sci, 2016, www.medecinesciences.org.

Valbiotis’ therapeutic areas